RxDoctor Payments Data

Sandra Force-Obrowski, MD

Family Medicine · Rancho Cucamonga, CANPI 1023034873

Payments from drug & device makers

$15,383in general payments, 2019–2025

Across 628 payments — averaging $24.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • Lilly USA, LLC$763
  • Abbott$634
  • Axsome Therapeutics, Inc.$595
  • Amgen$578
  • plus $7K from 34 others

What the payments were for

  • Food & beverage$15,25199%
  • Education$1321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,383 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$35,556
Medicare patients
95
Services billed
485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol141$135,607
OzempicSemaglutide51$70,603
JanuviaSitagliptin Phosphate34$45,683
EliquisApixaban31$34,881
JardianceEmpagliflozin30$34,434
XareltoRivaroxaban50$32,468
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$31,515
TrulicityDulaglutide26$24,676
EntrestoSacubitril/Valsartan25$22,664
MounjaroTirzepatide18$18,537
MyrbetriqMirabegron13$16,195
Breo ElliptaFluticasone/Vilanterol22$12,746
KerendiaFinerenone14$8,782
SynthroidLevothyroxine Sodium111$8,538
Janumet XrSitagliptin Phos/Metformin Hcl12$6,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$3,048$135,607141 claims
Novo NordiskOzempic$396$70,60351 claims
MerckJanuvia, Janumet Xr, Belsomra$359$56,94357 claims
GSKTrelegy Ellipta, Breo Ellipta$573$44,26165 claims
Lilly USA, LLCTrulicity, Mounjaro$763$43,21444 claims
PfizerEliquis$381$34,88131 claims
Boehringer IngelheimJardiance$440$34,43430 claims
Johnson & JohnsonXarelto$395$32,46850 claims
NovartisEntresto$322$22,66425 claims
Astellas Pharma US IncMyrbetriq$410$16,19513 claims
BayerKerendia$466$8,78214 claims
AbbVieSynthroid$2,478$8,538111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Rancho Cucamonga

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →